^
Association details:
| Biomarker: | FLT3-ITD mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Vanflyta (quizartinib) (FLT3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia
Excerpt:
...- FLT3-ITD mutated patients with relapsed/refractory AML (up to four prior therapeutic regimens for AML i.e. up to salvage 4 AML), including patients who may have been previously exposed to prior FLT3-inhibitor/s other than quizartinib (stem cell transplant [SCT] or stem cell therapy for patients who previously underwent SCT/stem cell therapy in remission will...
Trial ID:
Source:
Title:
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Excerpt:
...- Detection of FLT3-ITD mutation or FLT3-ITD/TKD co-mutations in bone marrow and/or peripheral blood samples within 30 days prior to study enrollment....
Trial ID:
Less C2 evidence
Source:
Title:
158 Phase I/II Study of Quizartinib, Venetoclax, and Decitabine Triple Combination in FLT3-ITD Mutated AML
Published date:
11/02/2023
Excerpt:
The combination of DAC + VEN + Quiz demonstrated activity in heavily pretreated and prior FLT3i-exposed (including 78% with prior gilteritinib exposure) R/R FLT3-ITDm pts, with a CRc rate of 68% and a median OS of 7.1 months.
Secondary therapy:
decitabine
Source:
Title:
Quizartinib (QUIZ) with decitabine (DAC) and venetoclax (VEN) is active in patients (pts) with FLT3-ITD mutated acute myeloid leukemia (AML): A phase I/II clinical trial.
Published date:
05/26/2022
Excerpt:
Of 5 patients with newly diagnosed AML (median age 69), all achieved CRc (2 CR, 3 CRi) with 4/5 and 2/4 responders FLT3-PCR and MFC negative...DAC + VEN + QUIZ is active in R/R FLT3-ITD mutated AML pts, with CRc rates of 78% and the median OS of 7.6 months.
Secondary therapy:
decitabine
DOI:
10.1200/JCO.2022.40.16_suppl.7036
Trial ID:
Source:
Title:
QUIZARTINIB WITH DECITABINE AND VENETOCLAX (TRIPLET) IS ACTIVE IN PATIENTS WITH FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA - A PHASE I/II STUDY
Published date:
05/12/2022
Excerpt:
With a median follow-up (f/u) of 13 months, the median OS was 7.6 months in R/R cohort. Median OS in prior Gilt exposed pts was 6.3 months and ≥1 prior FLT3i exposed pts was 6.3 months. 8/18 R/R pts (including 5/8 prior Gilt exposed pts) underwent ASCT with a median OS of 19 vs 8 months in pts who underwent ASCT versus not (p=0.26). Of the 5 frontline responding pts median OS was 14.5, 2 were alive in CR, 1 died in CR1 post-ASCT, 2 died due to progressive disease at the last f/u. DAC + VEN + QUIZ is active in R/R FLT3-ITD mutated AML pts, with CRc rates of 78% and the median OS of 7.6 months. The high response rate was maintained in prior Gilteritinib exposed pts. Interestingly, RAS/MAPK mutations but not emergent TKD mutations were associated with primary and secondary resistance to the triplet.
Secondary therapy:
decitabine
Source:
Title:
Quizartinib (Quiz) with Decitabine (DAC) and Venetoclax (VEN) Is Highly Active in Patients (pts) with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) – RAS/MAPK Mutations Continue to Drive Primary and Secondary Resistance
Published date:
11/04/2021
Excerpt:
We evaluated the Quiz, VEN, and DAC triple combination in pts with R/R or ND FLT3m AML....DAC + VEN + Quiz is active in heavily pretreated and prior FLT3i exposed (including 68% with prior gilteritinib) R/R FLT3-ITDm pts, with a CRc rate of 65% and a med OS of 7.5 months, 1-year OS 34%.
Secondary therapy:
decitabine
DOI:
10.1182/blood-2021-153426
Source:
Title:
QUIZARTINIB WITH DECITABINE AND VENETOCLAX (TRIPLET) IS HIGHLY ACTIVE IN PATIENTS WITH FLT3-ITD MUTATED ACUTE MYELOID LEUKEMIA
Published date:
05/12/2021
Excerpt:
DAC + VEN + quizartinib is active in heavily pretreated and prior FLT3i exposed R/R FLT3-ITDm pts, with CRc rates of 69% (55% of responders were negative MRD by MFC) and the med OS of 7.1 months. The regimen was well tolerated with no 30-day mortality.
Secondary therapy:
decitabine
